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BACKGROUND: The mechanism of aging goes along with age, one of which is characterized by cellular senescent, which occurs mostly in adipose 
tissue. Adipose tissue is the site of accumulation of large cell 
senescent, in the regulation of obesity and aging. Proteins 
p53 is marker for cell senescent, which are also known to 
induce inflammation. This study was aimed to determine 
the relationship between circulating protein p53 and high 
sensitivity C-reactive protein (hsCRP) in central obese men 
with inflammaging.
METHODS: The study design is an observational study 
with cross-sectional approach. The subjects were 75 central 
obese men (waist circumference/WC > 90 cm), aged ≥ 45 
years old. Subjects were divided into 2 age groups, those 
are middle age group: 45-59 years old (50.7%) and elderly 
group: ≥ 60 years old (49.3%). Examination of circulating 
p53 was done using enzyme-linked immunosorbent assay 
(ELISA) method, and the hsCRP examination was done by 
chemiluminescent method.  
RESULTS: It was found that there was a correlation 
between circulating p53 and hsCRP in elderly (r=-0.414; 
p<0.05) but not in middle age (r=-0.127; p=0.449).
CONCLUSION: From this study, it is assumed that more 
senescence cells in elderly are resulting in increased chronic 
inflammation.
KEywORDS: aging, senescent, inflammaging, protein 
p53, hsCRP
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Abstract
Introduction
Obesity is defined as an abnormal or excessive condition of 
fat accumulation in adipose tissue that may interfere with 
health.(1) Obesity in individuals with excess fat in the intra-
abdominal depot (abdomen) or central obesity is more at 
risk of disease due to obesity. According to the World Health 
Organization (WHO) criteria used by the Indonesian Basic 
Health Research, central obesity is expressed by the size of 
waist circumference (WC) > 90 cm for men or WC > 80 
cm for women.(2) Because of hormonal differences, women 
who are overweight tend to have more subcutaneous adipose 
tissue, while overweight men show a central increase in 
obesity and are therefore more susceptible to metabolic 
complications.(3,4)
 In obesity, there is a concept of low-grade chronic 
inflammation called meta-inflammation. Along with aging, 
the concept of low-grade chronic inflammation is known 
as inflammaging (inflammation and aging).(5)  Cytokines 
such as tumor necrosis factor-α (TNF-α) and interleukin-6 
(IL-6) and acute phase proteins such as high-sensitive C 
Reactive Protein (hsCRP) increase in obesity.(6) Unlike 
other markers of inflammation, CRP levels are stable over 
long periods, have no diurnal variation, and can be measured 
inexpensively with available high-sensitivity assays.(7)
 Inflammaging is caused by a senescent cell. 
Senescence is the cellular response to damage and stress. 
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Continuous senescent cells can accelerate aging and age-
related pathology by secreting secretions, senescence-
associated secretory phenotype (SASP). Mechanically, 
senescent cells can cause age-related diseases because they 
secrete a lot of proinflammatory cytokines (which are called 
SASP) that can modify the environment in tissues and alter 
normal cell function.(8,9)
 Adipose tissue is the site of accumulation senescent 
cells, in the setting of obesity and aging. Cellular senescence 
is irreversible, in which cells stop dividing in response to 
telomere shortening, oncogene activation, or metabolic 
stress. The senescent cell has a larger phenotype, showing 
the positivity associated with beta-galactosidase aging 
cell activity, and can secrete many chemokines, cytokines, 
growth factors, and metalloproteinase matrices.(10) Cell 
aging may contribute to age-related adipogenesis and 
lipodystrophy.(11)
 Many stimuli can cause aging. This mechanism of 
aging is characterized by multiple pathways. The common 
aging marker consists of the mediator of the cell senescent 
themselves, such as p16, ADP ribosylation factors (ARF), 
p53, p21, p15, p27 and hypophosphorylated RB.(12) The 
p53 is an important mediator of cellular response to cellular 
aging.(13) Expression of p53 in adipose tissue increases 
with increasing body mass index (BMI). It increased in the 
fat cell fraction of subjects with diabetes whose adipocyte 
cells were aged.(11) Expression of p53 in visceral fat obese 
rats increased compared with rats whose nutrients were 
limited.(14) The p53 levels in the blood on the subject of 
central obesity not yet discovered.
 After knowing the risks that can occur due to central 
obesity, as well as the link between obesity, aging and 
inflammatory processes (inflammaging), it is necessary 
to research the relationship between circulating protein 
p53 and hsCRP so that it is expected to become the basis 
of prevention and intervention to make early prevention 
strategies in individuals with central obesity.
Methods
The design of this study is an observational study with 
cross-sectional approach. The subjects of the study were 
obese adult men, age ≥ 45 years, WC > 90cm, which would 
be divided into 2 groups, based on WHO criteria: middle 
age: 45-59 years old and elderly: ≥ 60 years old.  
 The number of samples needed in this study is 
calculated by using the formula for quantitative variables 
by Charan and Biswas.(15) Inclusion criteria were central 
obese man (WC> 90 cm), aged ≥ 45 years. Exclusion criteria 
were liver function impairment (serum glutamic oxaloacetic 
transaminase (SGOT)/serum glutamic pyruvic transaminase 
(SGPT)> 2 times normal value), acute infection (hsCRP> 
10 mg/L), suffering from cancer or undergoing cancer 
treatment (based on interview).
 Subjects  were  selected  from  patients  of  Prodia 
Clinical Laboratory in Jakarta, Bogor, Bandung and 
Semarang, from November to December 2017. Laboratory 
analysis for initial screening was done at Prodia Clinical 
Laboratory. This protocol has been approved by the Ethics 
Commission of Padjadjaran University No. 1026/UN6.C.10/
PN/2017.
 Materials used in this study were human serum, 
enzyme-linked immunosorbent assay (ELISA) assay kit 
for p53 (Bender MedSystems GmbH, Vienna, Austria) and 
hsCRP assay kit (Cat. No. #L2KCRP2, Siemens, Cambridge, 
UK). Data is processed through SPSS for Windows 24.00 
(SPSS Inc., Chicago, USA). For statistical tests, the 
significance level used is 5%. Spearman correlation test was 
conducted for data analysis.
Results
The initial number of subjects recruited was 86 subjects. 
Seventy-five subjects met the inclusion and exclusion 
criteria, clinical and biochemical features are shown in 
Table 1. 
Min Max Median Mean ± SD
45 73 59 57.49 ± 8.09
WC (cm) 91 125 100 102.77 ± 7.91
SGOT (U/L) 12 48 23 24.65 ± 7.21
SGPT (U/L) 8 68 29 31.88 ± 14.36
hsCRP(mg/L) 0.3 6.8 2.1 2.417 ± 1.656
p53 (IU/mL) 0.03 14.76 0.19 1.216 ± 3.012
Characteristic 
(n=75)
Age (years)
Clinical
Biochemistry
Table 1. General characteristics of subjects.
Min: minimum value; Max: maximum value; SD: standard 
deviation; WC: waist circumference; SGOT: serum glutamic 
oxaloacetic transaminase; SGPT: serum glutamic pyruvic 
transaminase.
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Median Mean ± SD Median Mean ± SD
49 50.53 ± 4.29 64 64.65 ± 3.46 0.000*
WC (cm) 100.5 102.45 ± 8.18 100 103.11 ± 7.72 0.683
SGOT (U/L) 23 25.55 ± 6.46 23 23.73 ± 7.88 0.23
SGPT (U/L) 31.5 34.92 ± 14.70 25 28.76 ± 13.48 0.038*
hsCRP(mg/L) 2.5 2.82 ± 1.80 1.6 2.00 ± 1.40 0.035*
P53 (IU/mL) 0.19 1.21 ± 3.24 0.19 1.22 ± 2.80 0.652
Age (year)
Clinical
Biochemistry
Middle-aged 
(n=38)
Elderly
(n=37) pCharacteristic
Table 2. General characteristics of subject by age.
 Subjects were divided according to age criteria 
recommended  by  WHO,  as  follow  middle age:  45-59 
years old (50.7%) and elderly: 60 years and above (49.3%). 
The  descriptive  test  based  on  age  group  as  shown  in 
Table 2. 
Correlation of Circulating Protein p53 with 
Inflammatory Conditions
To see the interaction between circulating p53 and 
inflammatory variable, Spearman correlation test was 
performed. The correlation result showed circulating 
Protein p53 correlated with hsCRP in elderly with r=-0.414 
and p=0.011. Meanwhile there was no correlation shown in 
the middle age group (r=-0.127, p=0.449).
SD: standard deviation; WC: waist circumference; SGOT: serum glutamic oxaloacetic transaminase; 
SGPT: serum glutamic pyruvic transaminase; *p<0.05 (Mann Whitney).
Discussion
In the elderly, low-grade inflammation (inflammaging) is a 
risk factor for age-related diseases and physical weakness. 
Inflammaging is characterized by increased concentrations 
of proinflammatory cytokines. In he previous studies was 
found  that  proinflammatory  cytokines  stimulate  synthesis 
of CRP in the liver, and its levels increase in the elderly. 
(16)  New  research  conducted  by  Puzianowska-Kuźnicka, 
et  al.,  said  that  hsCRP  is a  proinflammatory  cytokine 
that  can illustrate the risk of mortality in the subject of the 
elderly.(17)
 This study found that circulating p53 correlates to 
hsCRP in elderly. As has been said before, p53 is a mediator 
of cell senescence where cellular senescence will be more 
common in elderly than middle age.(13,15) In addition, 
the possibility of cells becoming senescence due to the 
mechanism of cell damage that continues to occur on elderly. 
In the middle age there is no correlation between circulating 
p53 and hsCRP. This result may be caused by various factors. 
Drugs consumed by the subject (antioxidants or metformin) 
are known to improve aging. In the aging process, the 
senescent cell secretes SASP which will induce the immune 
system to clear senescent cells.(18) In subjects with a good 
immune system, the process of cleaning will work well, on 
the contrary if the immune system on the subject decreases, 
the senescent cells will accumulate more. 
 Inflammaging is caused by the presence of cells that 
are senescent. Continuous senescent cells can accelerate 
aging and age-related pathology by secreting SASP, it 
causeses age-related diseases because they secrete a 
lot of proinflammatory cytokines resulting in chronic 
inflammation.(8,9,11) 
 In this study, the negative correlation of circulating p53 
and hsCRP in elderly indicates that the low concentration 
of p53 in circulation is inversely proportional to hsCRP 
concentration. Low levels of circulating p53 signify the 
senescent cells so that the possibility of p53 is more in the 
intracell. This is supported by high concentrations of hsCRP 
because senenscent cells can cause inflammation caused by 
SASP (Figure 1). 
 From the follow-up analysis it was found that in the 
middle-aged group with high p53 as much as 66.7% had hs-
CRP with an intermediate risk of 1-3 mg/L. Whereas in the 
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Figure 1. Inflammation caused by senescent cells.(19)
Conclusion
Our study found a lower hsCRP level in elderly compared 
to the middle age subjects, due to the elderly consumption 
of anti-inflammatory agents. The correlation between 
circulating p53 and hsCRP in elderly, and a combination of 
low p53 and high hsCRP found in most elderly subjects, 
make a suggestion that cell death in elderly favorably 
occurred via cell senescence rather than apoptosis.
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elderly group with low p53, 62.5% had high risk of hs-CRP 
> 3 mg/L.
 Limitations in this study are the difficulty of getting 
subjects who do not take medication. Most middle-aged and 
elderly subjects start taking drugs, such as anti-inflammatory, 
so that in this study the drug factor can be a confounding 
factor in the results of the study. Another limitation is that 
researchers excluded the subjects who suffered from cancer 
only from questionnaires, where there might be subjects 
who did not know he had cancer because the subject of 
cancer can affect circulating p53 protein levels.
